BD/Bard: Building Critical Mass in a Cost-Constrained World

article image

BD’s recently announced $24-billion deal to buy CR Bard not only fills important technology gaps for BD and takes the company into new, higher-growth therapeutic device markets, it also enables BD to gain economic leverage through critical mass. In so doing, it is the latest mega-deal to advance a “post-technology vision” of the medtech market.

Size matters for medtech companies today, and Becton Dickinson Inc.’s (BD) recently announced $24-billion cash and stock mega-deal to acquire CR Bard is the latest case in point.


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: